-
Trump signs spending bill ending US government shutdown
-
Arsenal sink Chelsea to reach League Cup final
-
Leverkusen sink St Pauli to book spot in German Cup semis
-
'We just need something positive' - Monks' peace walk across US draws large crowds
-
Milan close gap on Inter with 3-0 win over Bologna
-
No US immigration agents at Super Bowl: security chief
-
NASA Moon mission launch delayed to March after test
-
Spain to seek social media ban for under-16s
-
LIV Golf events to receive world ranking points: official
-
US House passes spending bill ending government shutdown
-
US jet downs Iran drone but talks still on course
-
UK police launching criminal probe into ex-envoy Mandelson
-
US-Iran talks 'still scheduled' after drone shot down: White House
-
Chomsky sympathized with Epstein over 'horrible' press treatment
-
French prosecutors stick to demand for five-year ban for Le Pen
-
Russia's economic growth slowed to 1% in 2025: Putin
-
Bethell spins England to 3-0 sweep over Sri Lanka in World Cup warm-up
-
Nagelsmann backs Ter Stegen for World Cup despite 'cruel' injury
-
Homage or propaganda? Carnival parade stars Brazil's Lula
-
EU must be 'less naive' in COP climate talks: French ministry
-
Colombia's Petro meets Trump after months of tensions
-
Air India inspects Boeing 787 fuel switches after grounding
-
US envoy evokes transition to 'democratic' Venezuela
-
Syria govt forces enter Qamishli under agreement with Kurds
-
WHO wants $1 bn for world's worst health crises in 2026
-
France summons Musk, raids X offices as deepfake backlash grows
-
Four out of every 10 cancer cases are preventable: WHO
-
Sacked UK envoy Mandelson quits parliament over Epstein ties
-
US House to vote Tuesday to end partial government shutdown
-
Eswatini minister slammed for reported threat to expel LGBTQ pupils
-
Pfizer shares drop on quarterly loss
-
Norway's Kilde withdraws from Winter Olympics
-
Vonn says 'confident' can compete at Olympics despite ruptured ACL
-
Germany acquires power grid stake from Dutch operator
-
Finland building icebreakers for US amid Arctic tensions
-
Petro extradites drug lord hours before White House visit
-
Disney names theme parks boss chief Josh D'Amaro as next CEO
-
Macron says work under way to resume contact with Putin
-
Prosecutors to request bans from office in Le Pen appeal trial
-
Tearful Gazans finally reunite after limited Rafah reopening
-
Iran president confirms talks with US after Trump's threats
-
Spanish skater allowed to use Minions music at Olympics
-
Fire 'under control' at bazaar in western Tehran
-
Howe trusts Tonali will not follow Isak lead out of Newcastle
-
Vonn to provide injury update as Milan-Cortina Olympics near
-
France summons Musk for 'voluntary interview', raids X offices
-
US judge to hear request for 'immediate takedown' of Epstein files
-
Russia resumes large-scale strikes on Ukraine in glacial temperatures
-
Fit-again France captain Dupont partners Jalibert against Ireland
-
French summons Musk for 'voluntary interview' as authorities raid X offices
Man who let snakes bite him 200 times spurs new antivenom hope
Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.
Four days later, he woke up from a coma.
"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.
This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.
From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.
Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.
After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.
But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.
The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.
This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes.
Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.
These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.
- 'Pain every time' -
Friede's first bite was from a harmless garter snake when he was five years old.
"I was afraid, I cried, I ran away," said Friede, now 57.
Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.
Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.
How antivenom is made has changed little over the last 125 years.
Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.
However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock.
"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.
He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.
"There is pain every time," he said.
- 'Proud' -
For years, the scientists he contacted to take advantage of his immunity refused to bite.
Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.
Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.
When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."
"I've been waiting for this call for a long time," came the response, Glanville said.
The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.
It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.
The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.
Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.
Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.
Friede said he was "proud" to have made a "small difference" in medical history.
Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.
But he hopes to get bitten by snakes again in the future.
"I do miss it," he said.
E.Borba--PC